This combination therapy can rapidly relieve clinical symptoms, improve clinical outcomes, and demonstrate a favorable safety profile.[7] Furthermore, TC combined with SCF in patients with severe infections has been shown to enhance coagulation function, reduce inflammatory markers, and decrease the incidence of adverse events.[8] In patients with pulmonary infections caused by carbapenem-resistant A. baumannii, TC combined with SCF has shown superior efficacy compared with carbapenem-based regimens.[9]. This evidence concerns the gene KITLG and infection.